Protherics PLC Notification of PDMR Interests London, UK; Brentwood, TN, US; 12 June 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 11 June 2007, the following options over ordinary shares in the Company ("Ordinary Shares") were granted under the terms of the Protherics PLC Long Term Incentive Plan at an exercise price of 2 pence per share: Name Position Number of Options Ian Scoular Director of Business Development 136,170 Nicholas Staples Director of Corporate Affairs 114,893 Sally Waterman Director of Research & Development 136,170 In addition, the following options were granted on 11 June 2007 under the terms of the Protherics PLC Deferred Bonus Plan at an exercise price of 2 pence per share: Name Position Number of Options Nicholas Staples Director of Corporate Affairs 42,553 Sally Waterman Director of Research & Development 31,914 Following the above grant of options, the above Persons Discharging Managerial Responsibility hold options over the following number of Ordinary Shares: Ian Scoular 972,894 Nicholas Staples 549,163 Sally Waterman 660,373 | Ends | For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Financial Dynamics - press enquiries London: Ben Atwell, Anna Keeble +44 (0) 20 7831 3113 New York: John Capodanno, Jonathan Birt +1 212 850 5600 Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange
Protherics PLC announces Director/PDMR Shareholding - 2
| Source: Protherics PLC
Cheshire, UK--(Marketwire - June 12, 2007) -